Fig 1.
Preparation of insulin samples.
Table 1.
Characteristics of medical devices.
Fig 2.
Chromatogram obtained with the UFLC-DAD method described for Novorapid®.
Table 2.
Parameters of the UFLC-DAD assay quantification.
Fig 3.
Area under the curve for Umuline rapide®: Human insulin (A) and metacresol (B).
Statistical difference (p = 0.05), NS = not significant.
Fig 4.
Area under curve for Novorapid®: Insulin aspart (A), phenol (B) and metacresol (C).
Statistical difference (p = 0.05), NS = not significant.
Fig 5.
Percentage recovery for Umuline rapide®: Human insulin (A) and metacresol (B) during a 24-hour infusion with infusion lines in PVC, PE and PE/PVC.
Fig 6.
Percentage recovery for Novorapid®: Insulin aspart (A), phenol (B) and metacresol (C) during a 24-hour infusion with infusion lines in PVC, PE and PE/PVC.
Fig 7.
Cumulative amounts during the first eight hours of infusion for Umuline rapide®: Human insulin (A) and metacresol (B) with infusion lines in PVC, PE, PE/PVC.
Statistical difference (p = 0.05), NS = not significant.
Fig 8.
Cumulative amounts during the first eight hours of infusion for Novorapid®: Insulin aspart (A), phenol (B) and metacresol (C) with infusion lines in PVC, PE, PE/PVC.
Statistical difference (p = 0.05), NS = not significant.
Fig 9.
Amount at T24h for Umuline rapide®: Human insulin (A) and metacresol (B) with infusion lines.
Statistical difference (p = 0.05), NS = not significant.
Fig 10.
Amount at T24h for Novorapid®: Insulin aspart (A), phenol (B) and metacresol (C) with infusion lines.
Statistical difference (p = 0.05), NS = not significant.
Table 3.
Comparison of recovery percentage of both insulins with PVC.
Table 4.
Comparison of recovery percentage of both insulins with PE.
Table 5.
Comparison of recovery percentage of both insulins with PE/PVC.